



A Molecular Probe for *In Vivo* Detection and Monitoring of HER2 Expression in Breast Cancer




TEDCO/NIH/NCI Technology Showcase

Jacek Capala

September 25, 2007



Technology: Affibody® Molecules



Antibody
150 kDa


Affibody® Molecule
6-7 kDa




Competitive Advantages

- High affinity and selectivity
- Robustness
- Rapid clearance
- Engineering flexibility
- Production flexibility


A Library of Possibilities



Directed Chemistry




Directed Chemistry



ABY-002 – Clinical P-o-C in SPECT with ^{111}In


SPECT using ^{111}In ABY-002: HER2 positive metastasis




PET using ^{18}F FDG: increased metabolism



Directed Chemistry



PET Imaging of a HER2-Positive Tumor



Serial whole body micro-PET images of mouse bearing HER2-positive tumor after i.v. injection of ^{18}F -Z_{HER2} Affibody molecule.

Commercial Applications

Diagnosis:

- Identification of patients for HER2-targeted therapies
- Monitoring of changes in HER2 expression as response to therapy

Therapy:

- HER2-targeted delivery of radionuclides or toxins

Collaboration Opportunities

- License of ^{18}F -labeled tracer (patent application pending)
- Tri-lateral CRADA with NCI and Affibody AB, Sweden

Contact Information

For further information contact:

Jacek Capala, Ph.D.
Head, Molecular Targeting Section
Radiation Oncology Branch
CCR/NCI/NIH
10 Center Drive
Building 10, Room 1B-37A
Bethesda, MD 20892
301 496 5457
capalaj@mail.nih.gov